An efficient helper-virus-free method for rescue of recombinant paramyxoviruses and rhadoviruses from a cell line suitable for vaccine development
- PMID: 16569439
- DOI: 10.1016/j.jviromet.2006.02.006
An efficient helper-virus-free method for rescue of recombinant paramyxoviruses and rhadoviruses from a cell line suitable for vaccine development
Abstract
Recovery of recombinant, negative-strand, nonsegmented RNA viruses from a genomic cDNA clone requires a rescue system that promotes de novo assembly of a functional ribonucleoprotein (RNP) complex in the cell cytoplasm. This is accomplished typically by cotransfecting permissive cells with multiple plasmids that encode the positive-sense genomic RNA, the nucleocapsid protein (N or NP), and the two subunits of the viral RNA-dependent RNA polymerase (L and P). The transfected plasmids are transcribed in the cell cytoplasm by phage T7 RNA polymerase (T7 RNAP), which usually is supplied by infection with a recombinant vaccinia virus or through use of a stable cell line that expresses the polymerase. Although both methods of providing T7 RNAP are effective neither is ideal for viral vaccine development for a number of reasons. Therefore, it was necessary to modify existing technology to make it possible to routinely rescue a variety of recombinant viruses when T7 RNAP was provided by a cotransfected expression plasmid. Development of a broadly applicable procedure required optimization of the helper-virus-free methodology, which resulted in several modifications that improved rescue efficiency such as inclusion of plasmids encoding viral glycoproteins and matrix protein, heat shock treatment, and use of electroporation. The combined effect of these enhancements produced several important benefits including: (1) a helper-virus-free methodology capable of rescuing a diverse variety of paramyxoviruses and recombinant vesicular stomatitis virus (rVSV); (2) methodology that functioned effectively when using Vero cells, a suitable substrate for vaccine production; and (3) a method that enabled rescue of highly attenuated recombinant viruses, which had proven refractory to rescue using published procedures.
Similar articles
-
Development of a hamster kidney cell line expressing stably T7 RNA polymerase using retroviral gene transfer technology for efficient rescue of infectious foot-and-mouth disease virus.J Virol Methods. 2009 Mar;156(1-2):129-37. doi: 10.1016/j.jviromet.2008.11.010. Epub 2008 Dec 31. J Virol Methods. 2009. PMID: 19095010
-
Optimization of plasmid-only rescue of highly attenuated and temperature-sensitive respiratory syncytial virus (RSV) vaccine candidates for human trials.J Virol Methods. 2008 Nov;153(2):196-202. doi: 10.1016/j.jviromet.2008.07.012. Epub 2008 Sep 6. J Virol Methods. 2008. PMID: 18722472
-
Efficient bunyavirus rescue from cloned cDNA.Virology. 2004 Dec 20;330(2):493-500. doi: 10.1016/j.virol.2004.10.009. Virology. 2004. PMID: 15567443
-
[The reverse genetics systems for human and animal RNA viruses].Sheng Wu Gong Cheng Xue Bao. 2004 May;20(3):311-8. Sheng Wu Gong Cheng Xue Bao. 2004. PMID: 15971597 Review. Chinese.
-
Recovery of negative-strand RNA viruses from plasmid DNAs: a positive approach revitalizes a negative field.Virology. 1998 Jul 20;247(1):1-6. doi: 10.1006/viro.1998.9250. Virology. 1998. PMID: 9683565 Review. No abstract available.
Cited by
-
Development of a duplex real-time RT-qPCR assay to monitor genome replication, gene expression and gene insert stability during in vivo replication of a prototype live attenuated canine distemper virus vector encoding SIV gag.J Virol Methods. 2015 Mar;213:26-37. doi: 10.1016/j.jviromet.2014.11.015. Epub 2014 Dec 5. J Virol Methods. 2015. PMID: 25486083 Free PMC article.
-
Single-Dose Trivalent VesiculoVax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge.J Virol. 2018 Jan 17;92(3):e01190-17. doi: 10.1128/JVI.01190-17. Print 2018 Feb 1. J Virol. 2018. PMID: 29142131 Free PMC article.
-
Nonhuman Primates Are Protected against Marburg Virus Disease by Vaccination with a Vesicular Stomatitis Virus Vector-Based Vaccine Prepared under Conditions to Allow Advancement to Human Clinical Trials.Vaccines (Basel). 2022 Sep 21;10(10):1582. doi: 10.3390/vaccines10101582. Vaccines (Basel). 2022. PMID: 36298451 Free PMC article.
-
Novel viral vectors in infectious diseases.Immunology. 2018 Jan;153(1):1-9. doi: 10.1111/imm.12829. Epub 2017 Sep 26. Immunology. 2018. PMID: 28869761 Free PMC article. Review.
-
Heparan sulfate proteoglycans serve as alternative receptors for low affinity LCMV variants.PLoS Pathog. 2021 Oct 14;17(10):e1009996. doi: 10.1371/journal.ppat.1009996. eCollection 2021 Oct. PLoS Pathog. 2021. PMID: 34648606 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous